Cancer therapies utilizing the camptothecins: A review of the in vivo literature

Molecular Pharmaceutics

Volumn 7, Issue 2, 2010, Pages 307-349

  Venditto, Vincent J ^a   Simanek, Eric E ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Camptothecins; Cancer therapy; In vivo; Polymer therapeutics; Topoisomerase I inhibitors

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; BELOTECAN; BMS 422461; BN 80927; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CAMPTOTHECIN SODIUM CARBOXYLATE; CARBOXYMETHYLDEXTRAN; CHIMMITECAN; DB 67; DIFLOMOTECAN; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GI 47211; GIMATECAN; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOCAMPTOTHECIN; IRINOTECAN; KARENITECIN; LIPOSOME; LURTOTECAN; NANOPARTICLE; NSC 609669; PHTHALIMIDE; RUBITECAN; SPI 355; STI 481; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLON TUMOR; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; HYDROGEL; IN VIVO STUDY; LEUKEMIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MICELLE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PANCREAS CANCER; PANCREAS TUMOR; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; THYROID CANCER; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS;

EID: 77950588535     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900243b     Document Type: Review

References (314)

1. Wall, M. E.; Wani, M. C.; Cooke, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata J. Am. Chem. Soc. 1966, 88, 3888-3890
2. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from taxus brevifolia J. Am. Chem. Soc. 1971, 93, 2325-2327
3. Slichenmyer, W. J.; Von Hoff, D. D. New natural products in cancer chemotherapy J. Clin. Pharmacol. 1990, 30, 770-788 (Pubitemid 20334336)
4. Wall, M. E. Camptothecin and Taxol: discovery to clinic Med. Res. Rev. 1998, 18, 299-314
5. Hsiang, Y.-H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J. Biol. Chem. 1985, 260, 14873-14878 (Pubitemid 16211028)
6. Thomsen, B.; Mollerup, S.; Bonven, B. J.; Frank, R.; Blocker, H.; Nielsen, O. F.; Westergaard, O. Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin EMBO J. 1987, 6, 1817-1823
7. Pommier, Y.; Covey, J. M.; Kerrigan, D.; Markovits, J.; Pham, R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators Nucleic Acids Res. 1987, 15, 6713-6731 (Pubitemid 17134366)
8. Jaxel, C.; Kohn, K. W.; Pommier, Y. Topoisomerase I interactions with SV40 DNA in the presence and absence of camptothecin Nucleic Acids Res. 1988, 16, 11157-11170 (Pubitemid 19008462)
9. Kjeldsen, E.; Mollerup, S.; Thomsen, B.; Bonven, B. J.; Bolund, L.; Westergaard, O. Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage J. Mol. Biol. 1988, 202, 333-342
10. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for site specific receptor site and a relation to antitumor activity Cancer Res. 1989, 49, 1465-1469 (Pubitemid 19088683)
11. Redinbo, M. R.; Stewart, L.; Kuhn, P.; Champoux, J. J.; Hol, W. G. J. Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA Science 1998, 279, 1504-1513 (Pubitemid 28217069)
12. Staker, B. L.; Hjerrild, K.; Feese, M. D.; Behnke, C. A.; Burgin, A. B., Jr.; Stewart, L. The mechanism of topoisomerase I poisoning by a camptothecin analog Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15387-15392 (Pubitemid 35403944)
13. Staker, B. L.; Feese, M. D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A. B., Jr. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex J. Med. Chem. 2005, 48, 2336-2345 (Pubitemid 40516428)
14. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond Nat. Rev. Cancer 2006, 6, 789-802 (Pubitemid 44450467)
15. Hotte, S. J.; Oza, A.; Winquist, E. W.; Moore, M.; Chen, E. X.; Brown, S.; Pond, G. R.; Dancey, J. E.; Hirte, H. W. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital phase II consortium study Ann. Oncol. 2006, 17, 334-340 (Pubitemid 43160126)
16. Anzai, H.; Frost, P.; Abbruzzese, J. L. Synergistic cytotoxicity with 2-deoxy-5-azacytidine and topotecan in vitro and in vivo Cancer Res. 1992, 52, 2180-2185
17. Romanelli, S.; Perego, P.; Graziella, P.; Cerenini, N.; Tortoreto, M.; Zunino, F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems Cancer Chemother. Pharmacol. 1998, 41, 385-390 (Pubitemid 28095754)
18. Crump, M.; Lipton, J.; Hedley, D.; Sutton, D.; Shepherd, F.; Minden, M.; Stewart, K.; Beare, S.; Eisenhauer, E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study Leukemia 1999, 13, 343-347 (Pubitemid 29108072)
19. Schmidt, F.; Schuster, M.; Strefer, J.; Schabet, M.; Weller, M. Topotecan-based combination chemotherapy for human malignant glioma Anticancer Res. 1999, 19, 1217-1221 (Pubitemid 29257561)
20. Raymond, E.; Burris, H. A.; Rowinsky, E. K.; Eckardt, J. R.; Rodriguez, G.; Smith, L.; Weiss, G.; von Hoff, D. D. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma Ann. Oncol. 1997, 8, 1003-1008 (Pubitemid 27475732)
21. Hammond, L. A.; Eckardt, J. R.; Ganapathi, R.; Burris, H. A.; Rodriguez, G. A.; Eckhardt, S. G.; Rothenberg, M. L.; Weiss, G. R.; Kuhn, J. G.; Hodges, S.; von Hoff, D. D.; Rowinsky, E. K. A phase I and traslational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide Clin. Cancer Res. 1998, 4, 1459-1467 (Pubitemid 28265229)
22. Britten, C. D.; Hilsenbeck, S. G.; Eckhardt, S. G.; Marty, J.; Mangold, G.; MacDonald, J. R.; Rowinsky, E. K.; von Hoff, D. D.; Weitman, S. D. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model Cancer Res. 1999, 59, 1049-1053 (Pubitemid 29135965)
23. Cao, S.; Rustum, Y. M. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose Cancer Res. 2000, 60, 3717-3721 (Pubitemid 32204557)
24. Wasserman, E.; Sutherland, W.; Esteban, C. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer Clin. Colorectal Cancer 2001, 1, 149-153
25. Mayer, L. D.; Janoff, A. S. Optimizing combination chemotherapy by controlling drug ratios Mol. Interventions 2007, 7, 216-223
26. Guichard, S.; Arnould, S.; Hennebelle, I.; Bugat, R.; Canal, P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo Anti-Cancer Drugs 2001, 12, 741-751 (Pubitemid 33001188)
27. Harasym, T. O.; Tardi, P. G.; Harasym, N. L.; Harvie, P.; Johnstone, S. A.; Mayer, L. D. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios Oncol. Res. 2007, 16, 361-374 (Pubitemid 47413252)
28. Kirichenko, A. V.; Rich, T. A.; Newman, R. A.; Travis, E. L. Potentiation of murine MCa-4 carcinoma radioreponse by 9-amino-20-(S)-camptothecin Cancer Res. 1997, 57, 1929-1933
29. Lamond, J. P.; Mehta, M. P.; Boothman, D. A. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation J. Neuro.-Oncol. 1996, 30, 1-6
30. Karaberis, E.; Mourelatos, D. Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics Teratog., Carcinog., Mutagen. 2000, 20, 141-146 (Pubitemid 30328999)
31. Lawson, K. A.; Anderson, K.; Snyder, R. M.; Simmons-Menchaca, M.; Atkinson, J.; Sun, L.-Z.; Bandyopadhyay, A.; Knight, V.; Gilbert, B. E.; Sanders, B. G.; Kline, K. Novel vitamine E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis Cancer Chemother. Pharmacol. 2004, 54, 421-431 (Pubitemid 39462967)
32. Lee, D. H.; Kim, S.-W.; Bae, K.-S.; Hong, J.-S.; Suh, C.; Kang, Y.-K.; Lee, J.-S. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer Clin. Cancer Res. 2007, 13, 6182-6186 (Pubitemid 350075079)
33. Duncan, R. The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2003, 2, 347-360 (Pubitemid 37361705)
34. Kabanov, A. V. Polymer genomics: An insight into pharmacology and toxicology of nanomedicines Adv. Drug Delivery Rev. 2006, 58, 1597-1621 (Pubitemid 44841931)
35. Duncan, R. Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 2006, 6, 688 - 701 (Pubitemid 44286001)
36. Green, J. J.; Langer, R.; Anderson, D. G. A combinatorial polymer library approach yields insight into nonviral gene delivery Acc. Chem. Res. 2008, 41, 749-759
37. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1985, 46, 6387-6392 (Pubitemid 17221789)
38. Greish, K.; Fang, J.; Inutsuka, T.; Nagamitsu, A.; Maeda, H. Macromolecular therapeutics: Advantages and prospects with special emphasis on solid tumor targeting Clin. Pharmacokinet. 2003, 42, 1089-1105 (Pubitemid 37357647)
39. Duncan, R. Polymer therapeutics for tumour specific delivery Chem. Ind. 1997, 262-263 (Pubitemid 127447813)
40. Mathijssen, R. H. J.; Verweij, J.; De Jonge, M. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations J. Clin. Oncol. 2002, 20, 81-87 (Pubitemid 34032599)
41. Derelanko, M. J. Toxicologist's pocket handbook, 2nd ed.; Informa Healthcare: New York, 2007.
42. IUPAC Compendium of Chemical Technology; International Union of Pure and Applied Chemistry: New York, 2003.
43. Gallo, R. C.; Whang-Peng, J.; Adamson, R. H. Studies on the antitumor activity, mechanism of action and cell cycle effects of camptothecin J. Natl. Cancer Inst. 1971, 46, 789 - 795
44. Wani, M. C.; Ronman, P. E.; Lindley, J. T.; Wall, M. E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues J. Med. Chem. 1980, 23, 554-560 (Pubitemid 10153550)
45. Adamovics, J. A.; Hutchinson, C. R. Prodrug analogs of the antitumor alkaloid camptothecin J. Med. Chem. 1979, 22, 310-314
46. Gabr, A.; Kuin, A.; Aalders, M.; El-Gawly, H.; Smets, L. A. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH Cancer Res. 1997, 57, 4811-4816 (Pubitemid 27468988)
47. Hsiang, Y.-H.; Liu, L. F.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Kirshenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues Cancer Res. 1989, 49, 4385-4389 (Pubitemid 19208330)
48. Giovanella, B. C.; Hinz, H. R.; Kozielski, A. J.; Stehlin, J. S.; Silber, R.; Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin Cancer Res. 1991, 51, 3052-3055
49. Scott, D. O.; Bindra, D. S.; Stella, V. J. Plasma pharmacokinetics of the lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats Pharm. Res. 1993, 10, 1451-1457
50. Scott, D. O.; Bindra, D. S.; Sutton, S. C.; Stella, V. J. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats Drug Metab. Dispos. 1994, 22, 438-442
51. Schaeppi, U.; Fleischman, R. W.; Cooney, D. A. Toxicity of Camptothecin (NSC-100880) Cancer Chemother. Rep. 1974, 5, 25-35
52. Gottlieb, J. A.; Guarino, A. M.; Call, J. B.; Oliverio, V. T.; Block, J. B. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC 100880) Cancer Chemother. Rep. 1970, 54, 461-470
53. Creaven, P. J.; Allen, L. M.; Muggia, F. M. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity Cancer Chemother. Rep. 1972, 56, 573-578
54. Muggia, F. M.; Creaven, P. J.; Hansen, H. H.; Cohen, M. N.; Selawry, D. S. Phase I clinical trials of weekly and daily treatment with camptothecin (NSC100880). Correlation with clincial studies Cancer Chemother. Rep. 1972, 56, 515-521
55. Gottlieb, J. A.; Luce, J. K. Treatment of malignant melanoma with camptothecin (NSC 100880) Cancer Chemother. Rep. 1972, 56, 103-105
56. Moertel, C. G.; Schutt, A. J.; Reitmeier, R. J.; Hahn, R. G. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer Cancer Chemother. Rep. 1972, 56, 95-101
57. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. Plant antitumor agents. I. Isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata J. Am. Chem. Soc. 1966, 88, 3888-3890
58. Wall, M. E.; Wani, M. C.; Natschke, S. M.; Nicholas, A. W. Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from camptotheca acuminata decne: total synthesis and biological activity J. Med. Chem. 1986, 29, 1553-1555
59. Wani, M. C.; Nicholas, A. W.; Wall, M. E. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogs J. Med. Chem. 1986, 29, 2358-2363
60. Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Wall, M. E. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogs. Structure-activity correlations J. Med. Chem. 1987, 30, 1774-1779 (Pubitemid 18020904)
61. Wani, M. C.; Nicholas, A. W.; Wall, M. E. Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5'(RS)-1,5-dioxo-5'-hydroxy-2'H,5'H,6'H- 6'-oxopyrano[3',4'-f]-6,8-tetrahydroindolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin J. Med. Chem. 1987, 30, 2317-2319
62. Nicholas, A. W.; Wani, M. C.; Manikumar, G.; Wall, M. E.; Kohn, K. W.; Pommier, Y. Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogs of camptothecin J. Med. Chem. 1990, 33, 972-978 (Pubitemid 20085901)
63. Sawada, S.; Matsuoka, S.; Nokata, K.; Nagata, H.; Furuta, T.; Yokokura, T.; Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins Chem. Pharm. Bull. 1991, 39, 3183-3188
64. Wadkins, R. M.; Bearss, D.; Manikumar, G.; Wani, M. C.; Wall, M. E.; von Hoff, D. D. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I Cancer Res. 2004, 64, 6679-6683 (Pubitemid 39297930)
65. Henne, W. A.; Doorneweerd, D. D.; Hilgebrink, A. R.; Kularatne, S. A.; Low, P. S. Synthesis and of a folate peptide camptothecin prodrug Bioorg. Med. Chem. Lett. 2006, 16, 5350 - 5355
66. Lu, H.; Lin, H.; Jiang, Y.; Zhou, X.; Wu, B.; Chen, J. Synthesis and antitumor activity of 20-O-linked succinate-based camptothecin ester derivatives Lett. Drug Des. Discovery 2006, 3, 83-86
67. Samor, C.; Guerrini, A.; Varchi, G.; Beretta, G. L.; Fontana, G.; Bombardelli, E.; Carenini, N.; Zunino, F.; Bertucci, C.; Fiori, J.; Battaglia, A. The role of polyamine architecture on the pharmacological activity of open lactone camptothecin-polyamine conjugates Bioconjugate Chem. 2008, 19, 2270-2279
68. Wani, M. C.; Wall, M. E. Plant antitumor agents. II. Structure of two new alkaloids from Camptotheca acuminata J. Org. Chem. 1969, 34, 1364-1367
69. Zhang, R.; Li, Y.; Cai, Q.; Liu, T.; Sun, H.; Chambless, B. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I Cancer Chemother. Pharmacol. 1998, 41, 257-267 (Pubitemid 28059912)
70. Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity J. Med. Chem. 1991, 34, 98-107
71. Uckun, F. M.; Stewart, C. F.; Reaman, G.; Chelstrom, L. M.; Jin, J.; Chandran-Langlie, M.; Waddick, K. G.; White, J.; Evans, W. E. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells Blood 1995, 85, 2817-2828
72. Friedman, H. S.; Houghton, P. J.; Schold, S. C.; Keir, S.; Bigner, D. D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Cancer Chemother. Pharmacol. 1994, 34, 171-174 (Pubitemid 24157983)
73. Houghton, P. J.; Cheshire, P. J.; Myers, L.; Stewart, C. F.; Synold, T. W.; Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors Cancer Chemother. Pharmacol. 1992, 31, 229-239
74. Pawlik, C. A.; Houghton, P. J.; Stewart, C. F.; Cheshire, P. J.; Richmond, L. B.; Danks, M. K. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays Clin. Cancer Res. 1998, 4, 1995-2002
75. McCabe, F. L.; Johnson, R. K. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan Cancer Invest. 1994, 12, 308-313
76. De Cesare, M.; Zunino, F.; Pace, S.; Pisano, C.; Pratesi, G. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts Eur. J. Cancer 2000, 36, 1558 - 1564 (Pubitemid 30619009)
77. Guichard, S.; Montazeri, A.; Chatelut, E.; Hennebelle, I.; Bugat, R.; Canal, P. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation Clin. Cancer Res. 2001, 7, 3222-3228 (Pubitemid 32963847)
78. Grochow, L. B.; Rowinsky, E. K.; Johnson, R.; Ludeman, S.; Kaufmann, S. H.; McCabe, F. L.; Smith, B. R.; Hurowitz, L.; DeLisa, A.; Donehower, R. C.; Noe, D. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer Drug Metab. Dispos. 1992, 20, 706-713
79. Haas, N. B.; LaCreta, F. P.; Walczak, J.; Hudes, G. R.; Brennan, J. M.; Ozols, R. F.; O'Dwyer, P. J. Phase I/pharmacokinetic study of topotecan by 24-h continuous infusion weekly Cancer Res. 1994, 54, 1220-1226 (Pubitemid 24108061)
80. O'Dwyer, P. J.; LaCreta, F. P.; Haas, N. B.; Halbherr, T.; Frucht, H.; Goosenberg, E.; Yao, K. S. Clinical, pharmacokinetic and biological studies of topotecan Cancer Chemother. Pharmacol. 1994, 34 (Suppl) S46-S52 (Pubitemid 24264044)
81. Rowinsky, E. K.; Grochow, L. B.; Hendricks, C. B.; Ettinger, D. S.; Forasteire, A. A.; Hurowitz, L. A.; McGuire, W. P.; Sartorius, S. E.; Lubejko, B. G.; Kaufmann, S. H.; Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor J. Clin. Oncol. 1992, 10, 647-656
82. Verweij, J.; Lund, B.; Beijnen, J. H.; Planting, A.; De Boer-Dennert, M.; Koier, I.; Rosing, H.; Hansen, H. H. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor Ann. Oncol. 1993, 4, 673-678 (Pubitemid 23291814)
83. Blaney, S. M.; Balis, F. M.; Cole, D. E.; Craig, C.; Reid, J. M.; Ames, M. M.; Krailo, M.; Reaman, G.; Hammond, D.; Poplack, D. G. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-h continuous infusion Cancer Res. 1993, 53, 1032-1036 (Pubitemid 23087903)
84. Wall, J. G.; Burris, H. A. I.; von Hoff, D. D.; Rodriguez, G.; Kneuper-Hall, R.; Shaffer, D.; O'Rourke, T.; Brown, T.; Weiss, G.; Clark, G.; McVea, S.; Brown, J.; Johnson, R.; Friedman, C.; Smith, B.; Mann, W. S.; Kuhn, J. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days Anti-Cancer Drugs 1992, 3, 337-345
85. Burris, H. A. I.; Awads, A.; Kuhn, J. G.; Eckardt, J. R.; Cobb, P. W.; Rinaldi, D. A.; Fields, S.; Smith, L.; von Hoff, D. D. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion Anti-Cancer Drugs 1994, 5, 394-402 (Pubitemid 24237069)
86. Kantarjian, H. M.; Beran, M.; Ellis, A.; Zwelling, L.; O'Brien, S.; Cazenave, L.; Koller, C.; Rios, M. B.; Plunkett, W.; Keating, M. J.; Estey, E. H. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia Blood 1993, 81, 1146-1151 (Pubitemid 23067348)
87. Rowinsky, E. K.; Adjei, A.; Donehower, R. C.; Gore, S. D.; Jones, R. J.; Burke, P. J.; Cheng, Y.-C.; Grochow, L. B.; Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia J. Clin. Oncol. 1994, 12, 2193-2203 (Pubitemid 24356039)
88. Pratt, C. B.; Stewart, C.; Santana, V. M.; Bowman, L.; Furman, W.; Ochs, J.; Marina, N.; Kuttesch, J. F.; Heideman, R.; Sandlund, J. T.; Avery, L.; Meyer, W. H. Phase I study of topotecan for pediatric patients with malignant solid tumors J. Clin. Oncol. 1994, 12, 539-543 (Pubitemid 24079896)
89. Gerrits, C. J. H.; Schellens, J. H. M.; Burris, H.; Eckardt, J. R.; Planting, A. S. T.; van der Burg, M. E. L.; Rodriguez, G. I.; Loos, W. J.; van Beurden, V.; Hudson, I.; von Hoff, D. D.; Verweij, J. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin) Clin. Cancer Res. 1999, 5, 69-75 (Pubitemid 29045179)
90. O'Reilly, E.; Donehower, R. C.; Rowinsky, E. K.; Ord, S.; Grochow, L. B. A phase II trial of topotecan in patients with previously untreated pancreatic cancer Anti-Cancer Drugs 1996, 7, 410-414 (Pubitemid 26249194)
91. Rowinsky, E. K.; Baker, S. D.; Burks, K.; O'Reilly, S.; Donehower, R. C.; Grochow, L. B. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study Ann. Oncol. 1998, 9, 173-180 (Pubitemid 28123619)
92. Hertzberg, R.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S. M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. Modification of the hydroxlactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity J. Med. Chem. 1989, 32, 715-720 (Pubitemid 19075732)
93. Yano, H.; Kayukawa, S.; Iida, S.; Nakagawa, C.; Oguri, T.; Sanda, T.; Ding, J.; Mori, F.; Ito, A.; Ri, M.; Inagaki, A.; Kusumoto, S.; Ishida, T.; Komatsu, H.; Inagaki, H.; Suzuki, A.; Ueda, R. Overexpression of caboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma Cancer Sci. 2008, 99, 2309-2314
94. Dodds, H. M.; Haaz, M. C.; Riou, J. F.; Robert, J.; Rivory, L. P. Identification of a new metabolite of CPT-11 (Irinotecan): pharmacological properties and activation to SN-38 J. Pharmacol. Exp. Ther. 1998, 286, 578-583 (Pubitemid 28318036)
95. Haaz, M. C.; Rivory, L. P.; Riche, C.; Vernillet, L.; Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions Cancer Res. 1998, 58, 468-472 (Pubitemid 28087408)
96. Danks, M. K.; Yoon, K. J.; Bush, R. A.; Remack, J. S.; Wierdl, M.; Tsurkan, L.; Kim, S. U.; Garcia, E.; Metz, M. Z.; Najbauer, J.; Potter, P. M.; Aboody, K. S. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma Cancer Res. 2007, 67, 22-25 (Pubitemid 46142755)
97. Rivory, L. P.; Chatelut, E.; Canal, P.; Mathieu, B. A.; Robert, J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients Cancer Res. 1994, 54, 6330-6333
98. Kaneda, N.; Nagata, H.; Furuta, T.; Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse Cancer Res. 1990, 50, 1715-1720 (Pubitemid 20098809)
99. Ohno, R.; Okada, K.; Masaoka, T.; Kuramoto, A.; Arima, T.; Yoshida, Y. An early phase II study of CPT-11: a new derivative of camptothecin for the treatment of leukemia and lymphoma J. Clin. Oncol. 1990, 8, 1907-1912 (Pubitemid 20382355)
100. Masuda, N.; Fukuoka, M.; Kusunoki, Y.; Matsui, K.; Takifuji, N.; Kudoh, S.; Negoro, S.; Nishioka, M.; Nakagawa, K.; Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer J. Clin. Oncol. 1992, 10, 1225-1229
101. Pitot, H. C.; Adjei, A. A.; Reid, J. M.; Sloan, J. A.; Atherton, P. J.; Rubin, J.; Alberts, S. R.; Duncan, B. A.; Denis, L.; Schaaf, L. J.; Yin, D.; Sharma, A.; McGovern, P.; Miller, L. L.; Erlichman, C. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors Cancer Chemother. Pharmacol. 2006, 58, 165-172
102. Tsuruo, T.; Matsuzaki, T.; Matsshita, M.; Saito, H.; Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo Cancer Chemother. Pharmacol. 1988, 21, 71-74 (Pubitemid 18050487)
103. Pitot, H. C.; Wender, D.; O'Connell, M. J.; Schroeder, G.; Goldberg, R. M.; Rubin, J.; Mailliard, J. A.; Knost, J. A.; Ghosh, C.; Kirshling, R. J.; Levitt, R.; Windshitl, H. E. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma J. Clin. Oncol. 1994, 15, 2910-2919
104. Conti, J. A.; Kemeny, N. E.; Saltz, L. B.; Huang, Y.; Tong, W. P.; Chou, T.-C.; Sun, M.; Pulliam, S.; Gonzalez, C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer J. Clin. Oncol. 1996, 14, 709-715 (Pubitemid 26085513)
105. Verschraegen, C. F.; Levy, T.; Kudelka, A. P.; Llerena, E.; Ende, K.; Freedman, R. S.; Edwards, C. L.; Hord, M.; Steger, M.; Kaplan, A. L.; Kieback, D.; Fishman, A.; Kavanaugh, J. J. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix J. Clin. Oncol. 1997, 15, 625-631 (Pubitemid 27074231)
106. Rowinsky, E. K.; Grochow, L. B.; Ettinger, D. S.; Sartorius, S. E.; Lubejko, B. G.; Chen, T.-L.; Rock, M. K.; Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks Cancer Res. 1994, 54, 427-436 (Pubitemid 24979991)
107. Pitot, H. C.; Goldberg, R. M.; Reid, J. M.; Sloan, J. A.; Skaff, P. A.; Erlichman, C.; Rubin, J.; Burch, P. A.; Adjei, A. A.; Alberts, S. A.; Schaaf, L. J.; Elfring, G.; Miller, L. L. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solif tumor malignancy Clin. Cancer Res. 2000, 6, 2236-2244 (Pubitemid 30399189)
108. Rougier, P.; Bugat, R.; Douillard, J. Y.; Culine, S.; Suc, E.; Brunet, P.; Becouarn, Y.; Ychou, M.; Marty, M.; Extra, J. M.; Bonneterre, J.; Adenis, A.; Seitz, J. F.; Ganem, G.; Namer, M.; Conroy, T.; Negrier, S.; Merrouche, Y.; Burki, F.; Mousseau, M.; Herait, P.; Mahjoubi, M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil-based chemotherapy J. Clin. Oncol. 1997, 15, 251-260 (Pubitemid 27020581)
109. Raymond, E.; Boige, V.; Faivre, S.; Sanderink, G.-J.; Rixe, O.; Vernillet, L.; Jacques, C.; Gatineau, M.; Ducreux, M.; Armand, J. P. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction J. Clin. Oncol. 2002, 20, 4303-4312 (Pubitemid 35266290)
110. Boige, V.; Taiüeb, J.; Hebbar, M.; Malka, D.; Debaere, T.; Hannoun, L.; Magherini, E.; Mignard, D.; Poynard, T.; Ducreux, M. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level Eur. J. Cancer 2006, 42, 456-459 (Pubitemid 43227922)
111. Vassal, G.; Morizet, J.; Bissery, M.-C.; Boland, I.; Ardouin, P.; Mathieu-Boue, A.; Gouyette, A. Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblastoma xenografts Proc. Am. Assoc. Cancer Res. 1994, 35, 366
112. Savaraj, N.; Xu, R.; Wu, C. J.; Landy, H.; Chua, L.; Solomon, J.; Freun, L. Correlation of in vitro antitumor activity of irinotecan and topoisomerase I activity and levels in brain tumors Proc. Am. Assoc. Cancer Res. 1995, 14, 492
113. Armand, J. P.; Extra, Y. M.; Catimel, G.; Abigerges, D.; Marty, M.; Clavel, M. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies Ann. Oncol. 1996, 7, 837-842 (Pubitemid 26345875)
114. Masuda, N.; Kudoh, S.; Fukuoka, M. Irinotecan (CPT-11): Pharmacology and clinical applications Crit. Rev. Oncol. Hematol. 1996, 24, 3-26 (Pubitemid 26337052)
115. O'Reilly, S.; Rowinshy, E. K. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996 Crit. Rev. Oncol. Hematol. 1996, 24, 47-70 (Pubitemid 26337054)
116. Hare, C. B.; Elion, G. B.; Houghton, P. J.; Houghton, J. A.; Keir, S.; Marcelli, S. L.; Bigner, D. D.; Friedman, H. S. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts Cancer Chemother. Pharmacol. 1997, 39, 187-191 (Pubitemid 26414253)
117. Batchelor, T. T.; Gilbert, M. R.; Supko, J. G.; Carson, K. A.; Nabors, L. B.; Grossman, S. A.; Lesser, G. J.; Mikkelsen, T.; Phuphanich, S. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11 Neuro-Oncology 2004, 6, 21 - 27 (Pubitemid 38139635)
118. Taylor, J.; Amanze, A.; Di Federico, E.; Verschraegen, C. F. Irinotecan use during pregnancy Obstet. Gynecol. 2009, 114, 451-452
119. Potmesil, M.; Giovanella, B. C.; Liu, L. F.; Wall, M. E.; Silber, R.; Stehlin, J. S.; Hsiang, Y.-H.; Wani, M. C., Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10,11-methylenedioxy camptothecins. In DNA topoisomerases in cancer, Potmesil, M.; Kohn, K. W.; Liu, L. F.; Muggia, F. M.; Ross, W. E.; Silber, R., Eds.; Oxford University Press: 1991; pp 299-311.
120. Supko, J. G.; Malspeis, L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice Cancer Res. 1993, 53, 3062-3069 (Pubitemid 23210313)
121. Muggia, F. M.; Liebes, l.; Hazarika, M.; Wadler, S.; Hamilton, A.; Hornreich, G.; Sorich, J.; Chiang, C.; Newman, E.; Potmesil, M.; Hochster, H. Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days Anti-Cancer Drugs 2002, 13, 819-825
122. Eder, J. P., Jr.; Supko, J. G.; Lynch, T.; Bryant, M.; Vosburgh, E.; Shulman, L. N.; Xu, G.; Kufe, D. W. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-h continuous intravenous infusion Clin. Cancer Res. 1998, 4, 317-324 (Pubitemid 28122744)
123. Giovanella, B. C.; Stehlin, J. S.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Liu, L. F.; Silber, R.; Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts Science 1989, 246, 1046-1048 (Pubitemid 20010531)
124. Pantazis, P.; Hinz, H. R.; Mendoza, J. T.; Kozielski, A. J.; Williams, L. J., Jr.; Stehlin, J. S.; Giovanella, B. C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human xenografts in immunodeficient mice induced by camptothecins Cancer Res. 1992, 52, 3980-3987
125. Mattern, M. R.; Hofmann, G. A.; Polsky, R. M.; Funk, L. R.; McCabe, F. L.; Johnson, R. K. In vitro and in vivo effects of clinically important camptothecin analogs on multidrug-resistant cells Oncol. Res. 1993, 5, 467-474
126. Pantazis, P.; Kozielski, A. J.; Vardeman, D. M.; Petry, E. R.; Giovanella, B. C. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts Oncol. Res. 1994, 5, 273-281
127. Vokes, E. E.; Ansari, R. H.; Masters, G. A.; Hoffman, P. C.; Klepsch, A.; Ratain, M. J.; Sciortino, D. F.; Lad, T. E.; Krauss, S.; Fishkin, P. A. S.; Golomb, H. M. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer Ann. Oncol. 1998, 9, 1085 - 1090
128. Hochster, H.; Plimack, E. R.; Runowicz, C. D.; Speyer, J.; Wallach, R. C.; Sorich, J.; Mandeli, J.; Wadler, S.; Wright, J.; Muggia, F. M. Biweekly 72-h 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: Phase II study of the new york gynecologic oncology group and the eastern cooperative oncology group J. Clin. Oncol. 2004, 22, 120-126
129. Hinz, H. R.; Harris, N. J.; Natelson, E. A.; Giovanella, B. C. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)- camptothecin to 9-amino-20(S)-camptothecin in humans, dogs and mice Cancer Res. 1994, 54, 3096-3100
130. Chen, J.; Ping, Q.; Guo, J.; Chu, X.; Song, M. Pharmacokinetics of lactone, carboxylate and total 9-nitro-camptothecin with different doses and administration routes in rats Biopharm. Drug Dispos. 2006, 27, 53-59
131. Verschraegen, C. F.; Natelson, E. A.; Giovanella, B. C.; Kavanaugh, J. J.; Kudelka, A. P.; Freedman, R. S.; Edwards, C. L.; Ende, K.; Stehlin, J. S. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor Anti-Cancer Drugs 1998, 9, 36-44
132. Verschraegen, C. F.; Gupta, A.; Loyer, E.; Kavanaugh, J. J.; Kudelka, A. P.; Freedman, R. S.; Edwards, C. L.; Harris, N.; Steger, M.; Steltz, V.; Giovanella, B. C.; Stehlin, J. S. A phase II clinical and pharmacological study
133. Amorino, G. P.; Hercules, S. K.; Mohr, P. J.; Pyo, H.; Choy, H. Preclinical evaluation of the orally active camptothecin analog, RFS-20009-nitro-20(S)-camptothecin) as a radiation enhancer Int. J. Radiat. Oncol. Biol. Phys. 2000, 47, 503-509
134. Luzzio, M. J.; Besterman, J. M.; Emerson, D. L.; Evans, M. G.; Lackey, K.; Leitner, P. L.; McIntyre, G.; Morton, B.; Myers, P. L.; Peel, M.; Sisco, J. M.; Sternbach, D. D.; Tong, W.-Q.; Truesdale, A.; Uehling, D. E.; Vuong, A.; Yates, J. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I J. Med. Chem. 1995, 38, 395-401
135. Emerson, D. L.; Besterman, J. M.; Brown, H. R.; Evans, M. G.; Leitner, P. P.; Luzzio, M. J.; Shafffer, J. E.; Sternbach, D. D.; Uehling, D. E.; Vuong, A. In Vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues Cancer Res. 1995, 55, 603-609
136. Gerrits, C. J. H.; Creemers, G. J.; Schellens, J. H.; Wissel, P. S.; Planting, A. S. T.; Kunka, R.; Selinger, K.; De Boer-Dennert, M.; Marijnen, Y.; Harteveld, M.; Verweij, J. Phase I and pharmacological study of the new topoisomerase I inhibitor GI47211, using a daily x5 intravenous administration Br. J. Cancer 1996, 73, 744-750
137. Eckhardt, S. G.; Baker, S. D.; Eckardt, J.; Burke, T. G.; Warner, D. L.; Kuhn, J. G.; Rodriguez, G.; Fields, S.; Thurman, A.; Smith, L.; Rothenberg, M. L.; White, L.; Wissel, P. S.; Kunka, R.; DePee, S.; Littlefield, D.; Burris, H. A. I.; von Hoff, D. D.; Rowinsky, E. K. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks Clin. Cancer Res. 1998, 4, 595-604
138. Paz-Ares, L.; Kunka, R.; DeMaria, D.; Cassidy, J.; Alden, M.; Beranek, P.; Kaye, S.; Littlefield, D.; Reilley, D.; DePee, S.; Wissel, P. S.; Twelves, C.; O'Dwyer, P. J. A phase I clinical and pharmackinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br. J. Cancer 1998, 78, 1329-1336
139. Stevenson, J. P.; DeMaria, D.; Sludden, J.; Kaye, S. B.; Paz-Ares, L.; Grochow, L. B.; McDonald, A.; Selinger, K.; Wissel, P. S.; O'Dwyer, P. J.; Twelves, C. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann. Oncol. 1999, 10, 339-344
140. Schellens, J. H.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, S. B.; Dombernowsky, P.; Paridaens, R.; van Oosterom, A. T.; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, N.; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, C.; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies Invest. New Drugs 2002, 20, 83-93
141. Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H.; Pavlidis, N.; Verweij, J.; Sessa, C.; Kaye, S.; Roelvink, M.; Wanders, J.; Hanauske, A. Activity and toxicity of GI47211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study Ann. Oncol. 2000, 11, 793-797
142. Sessa, C.; Wanders, J.; Roelvink, M.; Dombernowsky, P.; Nielsen, D.; Morant, R.; Drings, P.; Wissel, P. S.; Hanauske, A.-R. Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC early clinical studies group (ECSG) Ann. Oncol. 2000, 11, 207-210
143. Rose, W. C.; Marathe, P. H.; Jang, G. R.; Monticello, T. M.; Balasubramanian, B. N.; Long, B.; Fairchild, C. R.; Wall, M. E.; Wani, M. C. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization Cancer Chemother. Pharmacol. 2006, 58, 73-85
144. Wadkins, R. M.; Potter, P.; Vladu, B.; Marty, J.; Mangold, G.; Weitman, S. D.; Manikumar, G.; Wani, M. C.; Wall, M. E.; von Hoff, D. D. Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts Cancer Res. 1999, 59, 3424-3428
145. Adams, D. J.; Dewhirst, M. W.; Flowers, J. L.; Gamcsik, M. P.; Colvin, O. M.; Manikumar, G.; Wani, M. C.; Wall, M. E. Camptothecin analogues with enhanced antitumor activity at acidic pH Cancer Chemother. Pharmacol. 2000, 46, 263-271
146. Flowers, J. L.; Hoffman, R. M.; Driscoll, T. A.; Wall, M. E.; Wani, M. C.; Manikumar, G.; Friedman, H. S.; Dewhirst, M. W.; Colvin, O. M.; Adams, D. J. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH Cancer Chemother. Pharmacol. 2000, 52, 253-361
147. Kim, D.-K.; Ryu, D. H.; Lee, J. Y.; Lee, N.; Kim, Y.-K.; Kim, J.-S.; Chang, K.; Im, G.-J.; Kim, T.-K.; Choi, W.-S. Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues J. Med. Chem. 2001, 44, 1594-1602
148. Sun, F.-X.; Tohgo, A.; Bouvet, M.; Yagi, S.; Nassirpour, R.; Moossa, A. R.; Hoffman, R. M. Efficacy of camptothecin analog DX-8951f (exatecan mesylate) on human pancreatic cancer in an orthotopic metastatic model Cancer Res. 2003, 63, 80-85
149. Mitsui, I.; Kumazawa, E.; Hirota, Y.; Aonuma, M.; Sugimori, M.; Ohsuki, S.; Uoto, K.; Ejima, A.; Terasawa, H.; Sato, K. A new water-soluble camptothecin derivative. DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo Jpn. J. Cancer Res. 1995, 86, 776-782
150. Takiguchi, S.; Kumazawa, E.; Shimazoe, T.; Tohgo, A.; Kono, A. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-1-resistant variants cultured in vitro and xenografted into nude mice Jpn. J. Cancer Res. 1997, 88, 760-769
151. Joto, N.; Ishii, M.; Minami, M.; Kuga, H.; Mitsui, I.; Tohgo, A. DX8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant Int. J. Cancer 1997, 72, 680-686
152. Lerchen, H.-G.; Baumgarten, J.; von dem Bruch, K.; Lehmann, T. E.; Sperzel, M.; Kempka, G.; Fiebig, H.-H. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents J. Med. Chem. 2001, 44, 4186-4195
153. Ishii, M.; Iwahana, M.; Mitsui, I.; Minami, M.; Imagawa, S.; Tohgo, A.; Ejima, A. Growth inhibitory effect of a new camptothecin analog, DX8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6 Anti-Cancer Drugs 2000, 11, 353-362
154. Kumazawa, E.; Jimbo, T.; Ochi, Y.; Tohgo, A. Potent and broad antitumor effects of DX-8951f, a water soluble camptothecin derivative, against various human tumors xenografted in nude mice Cancer Chemother. Pharmacol. 1998, 42, 210-220
155. Rowinsky, E. K.; Johnson, T. R.; Geyer, C. E. J.; Hammond, L. A.; Eckhardt, S. G.; Drengler, R.; Smetzer, L.; Coyle, J.; Rizzo, J.; Schwartz, G.; Tolcher, A.; von Hoff, D. D.; De Jager, R. L. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies J. Clin. Oncol. 2000, 18, 3151-3163
156. Royce, M. E.; Hoff, P. M.; Dumas, P.; Lassere, Y.; Lee, J. J.; Coyle, J.; Ducharme, M.; De Jager, R. L.; Pazdur, R. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog J. Clin. Oncol. 2001, 19, 1493-1500 (Pubitemid 32202558)
157. Garrison, M.; Hammond, L. A.; Geyer, C. E. J.; Schwartz, G.; Tolcher, A.; Smetzer, L.; Figueroa, J. A.; Ducharme, M.; Coyle, J.; Takimoto, C. H.; De Jager, R. L.; Rowinshy, E. K. A phase I and pharmacokinetic (PK) study of exatecan mesylate administered as a protratced 21-day infusion in patients with advanced solid malignancies Clin. Cancer Res. 2003, 9, 2527-2537 (Pubitemid 36842093)
158. Verschraegen, C. F.; Kudelka, A. P.; Hu, W.; Vincent, M.; Kavanaugh, J. J.; Loyer, E.; Bastien, L.; Duggal, A.; De Jager, R. L. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan Cancer Chemother. Pharmacol. 2004, 53, 1-7 (Pubitemid 38161182)
159. Giles, F. J.; Cortes, J. E.; Thomas, D. A.; Garcia-Manero, G.; Faderl, S.; Jeha, S.; De Jager, R. L.; Kantarjian, H. M. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia Clin. Cancer Res. 2002, 8, 2134-2141 (Pubitemid 34753583)
160. Boige, V.; Raymond, E.; Faivre, S.; Gatineau, M.; Meely, K.; Mekhaldi, S.; Pautier, P.; Ducreux, M.; Rixe, O.; Armand, J. P. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer J. Clin. Oncol. 2000, 18, 3986-3992
161. Minami, H.; Fujii, H.; Igarashi, T.; Itoh, K.; Tamanoi, K.; Oguma, T.; Sasaki, Y. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks Clin. Cancer Res. 2001, 7, 3056-3064 (Pubitemid 32963824)
162. Braybrooke, J. P.; Boven, E.; Bates, N. P.; Ruijter, R.; Dobbs, N.; Cheverton, P. D.; Pinedo, H. M.; Talbot, D. C. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies Ann. Oncol. 2003, 14, 913-921 (Pubitemid 36827208)
163. Sharma, S.; Kemeny, N.; Schwartz, G. K.; Kelsen, D.; O'Reilly, E.; Ilson, D.; Coyle, J.; De Jager, R. L.; Ducharme, M. P.; Kleban, S.; Hollywood, E.; Saltz, L. B. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-h infusions three of every four weeks Clin. Cancer Res. 2001, 7, 3963-3970 (Pubitemid 34044614)
164. Esteva, F. J.; Rivera, E.; M., C.; Valero, V.; Royce, M.; Duggal, A.; Colucci, P.; De Jager, R.; Hortobagyi, G. N. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma Cancer 2003, 98, 900-907 (Pubitemid 37022088)
165. Braybrooke, J. P.; Ranson, M.; Manegold, C.; Mattson, K.; Thatcher, N.; Cheverton, P.; Sekiguchi, M.; Suzuki, M.; Oyama, R.; Talbot, D. C. Phase II study of exatecan mesylate (DX8951f) as first line therapy for advanced non-small cell lung cancer Lung Cancer 2003, 41, 215-219 (Pubitemid 36842785)
166. Royce, M.; Rowinsky, E. K.; Hoff, P. M.; Coyle, J.; De Jager, R.; Pazdur, R.; Saltz, L. B. A phase II study of intravenous exatecan mesylate (DX8951-f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum Invest. New Drugs 2004, 22, 53-61 (Pubitemid 38196982)
167. Clamp, A.; Adams, M.; Atkinson, R.; Boven, E.; Calvert, A. H.; Cervantes, A.; Ganesan, T.; Lotz, J.; Vasey, P.; Cheverton, P.; Jayson, G. C. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer Gynecol. Oncol. 2004, 95, 114-119 (Pubitemid 39286285)
168. Ajani, J. A.; Takimoto, C.; Becerra, C. R.; Silva, A.; Baez, L.; Cohn, A.; Major, P.; Kamida, M.; Feit, K.; De Jager, R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer Invest. New Drugs 2005, 23, 479-484 (Pubitemid 41160095)
169. Abou-Alfa, G.; Rowinsky, E. K.; Patt, Y. Z.; Schwartz, G. K.; Kelsen, D. P.; Sharma, S.; Siegel, E.; Becerra, C. R.; Eckhardt, S. G.; Feit, K.; De Jager, R.; O'Reilly, E. M. A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers Am. J. Clin. Oncol. 2005, 28, 334-339
170. Reichardt, P.; Nielsen, O. S.; Bauer, S.; Hartmann, J. T.; Schoüffski, P.; Christensen, T. B.; Pink, D.; Daugaard, S.; Marreaud, S.; Van Glabbeke, M.; Blay, J. Y. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 2007, 43, 1017-1022 (Pubitemid 46486707)
171. Abou-Alfa, G.; Letourneau, R.; Harker, G.; Modiano, M.; Hurwitz, H.; Tchekmedyian, N. S.; Feit, K.; Ackerman, J.; De Jager, R. L.; Eckhardt, S. G.; O'Reilly, E. M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer J. Clin. Oncol. 2006, 24, 4441-4447 (Pubitemid 46630982)
172. Lee, J.-H.; Lee, J.-M.; Kim, J.-K.; Ahn, S.-K.; Lee, S.-J.; Kim, M.-Y.; Jew, S.-S.; Park, J.-G.; Hong, C. I. Antitumor activity of 7-[2-(N- isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor Arch. Pharm. Res. 1998, 21, 581-590 (Pubitemid 128668322)
173. Kim, J. C.; Shin, D. H.; Kim, S. H.; Kim, J. K.; Park, S. C.; Son, W. C.; Lee, H. S.; Suh, J. E.; Kim, C. Y.; Ha, C. S.; Chung, M. K. Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats Reg. Toxicol. Pharmacol. 2004, 40, 356-369
174. Chung, M.-K.; Kim, C.-Y.; Kim, J.-C. Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring Cancer Chemother. Pharmacol. 2007, 59, 383-395
175. Chung, M.-K.; Kim, J.-C.; Han, S.-S. Embryonic effects of CKD-602, a new camptothecin anticancer agent, in rats Reprod. Toxicol. 2005, 20, 165-173
176. Kim, J.-C.; Shin, D.-H.; Park, S.-H.; Park, S.-C.; Kim, Y.-B.; Kim, H.-C.; Cha, S.-W.; Cho, K.-H.; Kang, B.-H.; Chung, M.-K. 4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs Food Chem. Toxicol. 2005, 43, 699-706
177. Chung, M.-K.; Kim, J.-C.; Han, S.-S. Effects of CKD-602, a new camptothecin anticancer agent, on pregnant does and embryo-fetal development in rabbits Drug Chem. Toxicol. 2005, 1, 35-49
178. Lee, D. H.; Kim, S.-W.; Suh, C.; Lee, J.-S.; Lee, J.-H.; Lee, S.-J.; Ryoo, B. Y.; Park, K.; Kim, J. S.; Heo, D. S.; Kim, N. K. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study Ann. Oncol. 2008, 19, 123-127
179. Han, J.; Cha, S.-W.; Kim, C.-Y.; Lee, G.-S.; Suh, J.-E.; Kim, J.-K.; Kim, J.-C.; Kang, B.-H. Toxicity study of CKD-602, a camptothecin anticancer agent: 5-day repeated intravenous administration in rats J. Appl. Pharmacol. 2004, 12, 49-54
180. Kim, J. C.; Shin, D.-H.; Kim, S. H.; Kim, J. K.; Cha, S. W.; Han, J.; Suh, J. E.; Chung, M.-K. Acute toxicity of CKD-602, a new anticancer agent, in rats J. Appl. Pharmacol. 2004, 12, 43-48
181. Pollack, I. F.; Erff, M.; Bom, D.; Burke, T.; Strode, J. T.; Curran, D. P. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo Cancer Res. 1999, 59, 4898-4905 (Pubitemid 29472894)
182. Zamboni, W. C.; Jung, L. L.; Strychor, S.; Joseph, E.; Zamboni, B. A.; Fetterman, S. A.; Sidone, B. J.; Burke, T. G.; Curran, D. P.; Eiseman, J. L. Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice Invest. New Drugs 2008, 26, 399 - 406
183. Van Hattum, A. H.; Pinedo, H. M.; Schluper, H. M. M.; Hausheer, F. H.; Boven, E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer Int. J. Cancer 2000, 88, 260-266
184. Schellens, J. H.; Creemers, G. J.; Beijnen, J. H.; Rosing, H.; De Boer-Dennert, M.; McDonald, M.; Davies, B.; Verweij, J. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor Br. J. Cancer 1996, 73, 1268-1271 (Pubitemid 26162345)
185. Sparreboom, A.; De Jonge, M. J.; Punt, C. J.; Nooter, K.; Loos, W. J.; Porro, M. G.; Verweij, J. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors Clin. Cancer Res. 1998, 4, 1915-1919 (Pubitemid 28369175)
186. Van Hattum, A. H.; Schluper, H. M. M.; Hausheer, F. H.; Pinedo, H. M.; Boven, E. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance Int. J. Cancer 2002, 100, 22-29 (Pubitemid 34602060)
187. Hausheer, F. H.; Haridas, K.; Zhao, M.; Murali, D.; Seetharamulu, P.; Yao, S.; Reddy, D.; Pavankumar, P.; Saxe, J.; Qiuli, H.; Rustum, Y. M. Karenitecins: a novel class of orally active highly lipophilic topoisomerase I inhibitors Proc. Am. Assoc. Cancer Res. 1997, 38, 227
188. Hausheer, F. H.; Haridas, K.; Zhao, M.; Murali, D.; Seetharamulu, P.; Yao, S.; Reddy, D.; Pavankumar, P.; Wu, M.; Saxe, J.; Huang, Q.; Rustum, Y. M. Kerenitecins (part II): a novel class of orally active highly lipophilic topoisomerase I inhibitors Proc. Am. Assoc. Cancer Res. 1998, 39, 420
189. Kerr, J. Z.; Berg, S. L.; Hausheer, F. H.; Blaney, S. M. Karenitecins: cytotoxicity studies in pediatric tumor cell lines Proc. Am. Assoc. Cancer Res. 1999, 40, 112
190. Thompson, P. A.; Berg, S. L.; Aleksic, A.; Kerr, J. Z.; McGuffey, L.; Dauser, R.; Nuchtern, J. G.; Hausheer, F.; Blaney, S. M. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates Cancer Chemother. Pharmacol. 2004, 53, 527-532 (Pubitemid 38680251)
191. Daud, A.; Valkov, N.; Centeno, B.; Derderian, J.; Sullivan, P.; Munster, P.; Urbas, P.; DeConti, R. C.; Berghorn, E.; Liu, Z.; Hausheer, F. H.; Sullivan, D. Phase II trial of kerenitecin in patients with malignant melanoma: clinical and translational study Clin. Cancer Res. 2005, 11, 3009-3016 (Pubitemid 40525206)
192. Dallavalle, S.; Ferrari, A.; Biasotti, B.; Merlini, L.; Penco, S.; Gallo, G.; Marzi, M.; Tinti, M. O.; Martinalli, R.; Pisano, C.; Carminati, P.; Carenini, N.; Beretta, G.; Perego, P.; De Cesare, M.; Pratesi, G.; Zunino, F. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity J. Med. Chem. 2001, 44, 3264 - 3274 (Pubitemid 32917106)
193. De Cesare, M.; Pratesi, G.; Perego, P.; Carenini, N.; Tinelli, S.; Merlini, L.; Penco, S.; Pisano, C.; Bucci, F.; Vesci, L.; Pace, S.; Capocasa, F.; Carminati, P.; Zunino, F. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin Cancer Res. 2001, 61, 7189-7195 (Pubitemid 32946514)
194. Huang, M.; Gao, H.; Chen, Y.; Zhu, H.; Cai, Y.; Zhang, X.; Miao, Z.; Jiang, H.; Zhang, J.; Shen, H.; Lin, L.; Wei, L.; Ding, J. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo Clin. Cancer Res. 2007, 13 (4) 1298-1307 (Pubitemid 46424071)
195. Lavergne, O.; Lesueur-Ginot, L.; Pla Rodas, F.; Kasprzyk, P. G.; Pommier, J.; Demarquay, D.; Prevost, G.; Ulibarri, G.; Rolland, A.; Schiano-Liberatore, A.-M.; Harnett, J.; Pons, D.; Camara, J.; Bigg, D. C. H. Homocamptothecins: Synthesis and antitumor activity of novel E-ring modified camptothecin analogues J. Med. Chem. 1998, 41, 5410-5419
196. Larsen, A.; Gilbert, C.; Chyzak, G.; Plisov, S. Y.; Naguibneva, I.; Lavergne, O.; Lesueur-Ginot, L.; Bigg, D. C. H. Unusual potency of BN 80915, a novel fluoriated E-ring modified camptothecin, toward human colon carcinoma cells Cancer Res. 2001, 61, 2961-2967
197. Gelderbolm, H.; Salazar, R.; Verweij, J.; Pentheroudakis, G.; De Jonge, M. J.; Devlin, M.; van Hooije, C.; Seguy, F.; Obach, R.; Prunonosa, J.; Principe, P.; Twelves, C. Phase I and pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors Clin. Cancer Res. 2003, 9, 4101-4107
198. Scott, L.; Soepenberg, O.; Verweij, J.; De Jonge, M. J.; Th Planting, A. S.; McGovern, D.; Principe, P.; Obach, R.; Twelves, C. A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumors Ann. Oncol. 2007, 18, 569-575
199. Graham, J. S.; Falk, S.; Samuel, L. M.; Cendros, J. M.; Evans, T. R. J. A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy Cancer Chemother. Pharmacol. 2009, 63, 945-952
200. Lesueur-Ginot, L.; Demarquay, D.; Kiss, R.; Kasprzyk, P. G.; Dassonneville, L.; Bailly, C.; Camara, J.; Lavergne, O.; Bigg, D. C. H. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties Cancer Res. 1999, 59, 2939-2943
201. Demarquay, D.; Huchet, M.; Coulomb, H.; Lesueur-Ginot, L.; Lavergne, O.; Camara, J.; Kasprzyk, P. G.; Prevost, G.; Bigg, D. C. H. BN89027: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo Cancer Res. 2004, 64, 4942-4949
202. Fassberg, J.; Stella, J. V. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues J. Pharm. Sci. 1992, 81, 676-684
203. Cao, Z.; Harris, N.; Kozielski, A.; Vardeman, D.; Stehlin, J. S.; Giovanella, B. Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vivo pharmacokinetics, toxicity and antitumor activity J. Med. Chem. 1998, 41, 31-37
204. Cao, Z.; Pantazis, P.; Mendoza, J. T.; Early, J.; Kozielski, A.; Harris, N.; Liehr, J.; Stehlin, J. S.; Giovanella, B. Structure-activity relationship of alkyl 9-nitrocamptothecin esters Recent Res. Novel Med. Chem. 2001, 1, 157-171
205. Kolhatkar, R. B.; Swaan, P.; Ghandehari, H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers Pharm. Res. 2008, 25, 1723-1729
206. Morgan, M. T.; Nakanishi, Y.; Kroll, D. J.; Griset, A. P.; Carnahan, M. A.; Wathier, M.; Oberlies, N. H.; Manikumar, G.; Wani, M. C.; Grinstaff, M. W. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro Cancer Res. 2006, 66, 11913-11921
207. Zhang, W.; Jiang, J.; Qin, C.; Perez, L. M.; Parrish, A. R.; Safe, S. H.; Simanek, E. E. Triazine dendrimers for drug delivery: evaluation of solubilization properties, activity in cell culture, and in vivo toxicity of a candidate vehicle Supramol. Chem. 2003, 15, 607-616
208. Gopin, A.; Rader, C.; Shabat, D. New chemical adaptor unit designed to release a drug from a tumor targeting davice by enzymetic triggering Bioorg. Med. Chem. 2004, 12, 1853-1858
209. Pessah, N.; Reznik, M.; Shamis, M.; Yantiri, F.; Xin, H.; Bowdish, K.; Shomron, N.; Ast, G.; Shabat, D. Bioactivation of carbamate-based 20(S)-camptothecin prodrugs Bioorg. Med. Chem. 2004, 12, 1859-1866
210. Shamis, M.; Lode, H. N.; Shabat, D. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2 J. Am. Chem. Soc. 2004, 126, 1726-1731
211. Gopin, A.; Ebner, S.; Attali, B.; Shabat, D. Enzymatic activation of second-generation denritic prodrugs: canjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry Bioconjugate Chem. 2006, 17, 1432-1440
212. Erez, R.; Ebner, S.; Attali, B.; Shabat, D. Chemotherapeutic bone-targeted bisphophonate prodrugs with hydrolytic mode of activation Bioorg. Med. Chem. Lett. 2008, 18, 816-820
213. Venditto, V. J.; Allred, K.; Allred, C. D.; Simanek, E. E. Intercepting the synthesis of triazine dendrimers with nucleophilic pharmacophores: a general strategy toward drug delivery vehicles Chem. Commun. 2009, 37, 5541-5542
214. Parrish, B.; Emrick, T. Soluble camptothecin derivatives prepared by click cycloaddition chemistry on functional aliphatic polyesters Bioconjugate Chem. 2007, 18, 263-267
215. Mu, L.; Chrastina, A.; Levchenko, T.; Torchilin, V. P. Micelles from Poly(ethylene glycol)-phosphatidyl ethanolamine conjugates (PEG-PE) as pharmaceutical nanocarriers for poorly soluble drug camptothecin J. Biomed. Nanotechnol. 2005, 1, 190-195
216. Cabral, H.; Nakanishi, M.; Kumagai, M.; Jang, W.-D.; Nishiyama, N.; Kataoka, K. A photo-activated targeting chemotherapy using glutathione sensitive camptothecin-loaded polymeric micelles Pharm. Res. 2009, 26, 82-92
217. Liu, Z.; Robinson, J. T.; Sun, X.; Dai, H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs J. Am. Chem. Soc. 2008, 130, 10876-10877
218. Watanabe, M.; Kawano, K.; Yokoyama, M.; Opanasopit, P.; Okano, T.; Maitani, Y. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability Int. J. Pharm. 2006, 308, 183-189
219. Kawano, K.; Watanabe, M.; Yamamoto, T.; Yokoyama, M.; Opanasopit, P.; Okano, T.; Maitani, Y. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles J. Controlled Release 2006, 112, 329-332
220. Ding, X.-Q.; Chen, D.; Wang, A.-X.; Li, S.; Chen, Y.; Wang, J. Antitumor effects of hydroxycamptothecin-loaded poly[ethylene glycol]-poly[-benzyl-L- glutamate] micelles against oral squamous cell carcinoma Oncol. Res. 2007, 16, 313-323
221. Emerson, D. L. Liposomal delivery of camptothecins Pharm. Sci. Technol. Today 2000, 3, 205-209
222. Burke, T. G.; Staubus, A. E.; Mishra, A. K.; Malak, H. Liposomal stabilization of camptothecin's lactone ring J. Am. Chem. Soc. 1992, 114, 8318-8319
223. Burke, T. G.; Mishra, A. K.; Wani, M. C.; Wall, M. E. Lipid bilayer partitioning and stability of camptothecin drugs Biochemistry 1993, 32, 5352-5364
224. Sugarman, S. M.; Zou, Y.; Wasan, K.; Poirot, K.; Kumi, R.; Reddy, S.; Perez-Soler, R. Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies Cancer Chemother. Pharmacol. 1996, 37, 531-538
225. Watanabe, M.; Kawano, K.; Toma, K.; Hatori, Y.; Maitani, Y. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin J. Controlled Release 2008, 127, 231-238
226. Tardi, P.; Choice, E.; Masin, D.; Redelmeier, T.; Bally, M. B.; Madden, T. D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models Cancer Res. 2000, 60, 3389-3393 (Pubitemid 30482152)
227. Liu, J.-J.; Hong, R.-L.; Cheng, W.-F.; Hong, K.; Chang, F.-H.; Tseng, Y.-L. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation Anti-Cancer Drugs 2002, 13, 709-717
228. Messerer, C. L.; Ramsay, E. C.; Waterhouse, D.; Ng, R.; Simms, E. M.; Harasym, N.; Tardi, P.; Mayer, L. D.; Bally, M. B. Liposomal irinotecan: formulation deelopment and therapeutic assessment in murine xenograft models of colorectal cancer Clin. Cancer Res. 2004, 10, 6638-6649 (Pubitemid 39346561)
229. Drummond, D. C.; Noble, C. O.; Guo, Z.; Hong, K.; Park, J. W.; Kirpotin, D. B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy Cancer Res. 2006, 66, 3271-3277
230. Zhang, J. A.; Xuan, T.; Parmar, M.; Ma, L.; Ugwu, S.; Ali, S.; Ahmad, I. Development and characterization of a novel liposome-based formulation of SN-38 Int. J. Pharm. 2004, 270, 93-107 (Pubitemid 38077091)
231. Lei, S.; Chien, P.-Y.; Sheikh, S.; Zhang, A.; Ali, S.; Ahmad, I. Enhanced therapeutic efficacu of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice Anti-Cancer Drugs 2004, 15, 773-778 (Pubitemid 39281301)
232. Pal, A.; Khan, S.; Wang, Y.-F.; Kamath, N.; Sarkar, A. K.; Ahmad, A.; Sheikh, S.; Ali, S.; Carbnaro, D.; Zhang, A.; Ahmad, I. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation Anticancer Res. 2005, 25, 331-342 (Pubitemid 40470128)
233. Colbern, G. T.; Dykes, D. J.; Engbers, C.; Musterer, R.; Hiller, A.; Pegg, E.; Saville, R.; Weng, S.; Luzzio, M. J.; Uster, P.; Amantea, M.; Working, P. K. Encapsulation of the topoisomerase I inhibitor GL147211C in PEGylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts Clin. Cancer Res. 1998, 4, 3077-3082
234. Emerson, D. L.; Bendele, R.; Brown, E. B.; Chiang, S.; Desjardins, J. P.; Dihel, L. C.; Gill, S. C.; Hamilton, M.; LeRay, J. D.; Moon-McDermott, L.; Moynihan, K.; Richardson, F. C.; Tomkinson, B.; Luzzio, M. J.; Baccanari, D. Antitumor efficacy, pharmacokinetics and biodistribution of NX211: a low-clearance liposomal formulation of lurtotecan Clin. Cancer Res. 2000, 6, 2903-2912
235. Desjardins, J. P.; Abbott, E. A.; Emerson, D. L.; Tomkinson, B. E.; LeRay, J. D.; Brown, E. N.; Hamilton, M.; Dihel, L. C.; Ptaszynski, M.; Bendele, R. A.; Richardson, F. C. Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice Anti-Cancer Drugs 2001, 12, 235-245
236. Tomkinson, B.; Bendele, R.; Giles, F. J.; Brown, E. B.; Gray, A.; Hart, K.; LeRay, J. D.; Meyer, D.; Pelanne, M.; Emerson, D. L. OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL Leukemia Res. 2003, 27, 1039-1050
237. Kehrer, D. F. S.; Bos, A. M.; Verweij, J.; Groen, H. J.; Loos, W. J.; Sarreboom, A.; de Jonge, M. J. A.; Hamilton, M.; Cameron, T.; de Vries, E. G. E. Phase I and pharmacologic study of liposomal lurtotecan, NX211: Urinary excretion predicts hematologic toxicity J. Clin. Oncol. 2002, 20, 1222-1231
238. Giles, F. J.; Tallman, M. S.; Garcia-Manero, G.; Cortes, J. E.; Thomas, D. A.; Wierda, W. G.; Verstovek, S.; Hamilton, M.; Barrett, E.; Albitar, M.; Kantarjian, H. M. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia Cancer 2004, 100, 1449-1458
239. Gelmon, K.; Hirte, H. W.; Fisher, B.; Walsh, W.; Ptaszynski, M.; Hamilton, M.; Onetto, N.; Eisenhauer, E. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks with solid cancers Invest. New Drugs 2004, 22, 263-275 (Pubitemid 39012565)
240. Seiden, M. V.; Muggia, F. M.; Astrow, A.; Matulonis, U.; Campos, S.; Roche, M.; Sivret, J.; Rusk, J.; Barrett, E. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer Gynecol. Oncol. 2004, 93, 229-232
241. Duffaud, F.; Borner, M.; Chollet, P.; Vermorken, J. B.; Bloch, J.; Degardin, M.; Rolland, F.; C., D.; Baron, B.; Lacombe, D.; Fumoleau, P. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group Study Eur. J. Cancer 2004, 40, 2748-2752
242. Dark, G. G.; Calvert, A. H.; Grimshaw, R.; Poole, C.; Swenerton, K.; Kaye, S.; Coleman, R.; Jayson, G.; Le, T.; Ellard, S.; Trudeau, M.; Vasey, P.; Hamilton, M.; Cameron, T.; Barrett, E.; Walsh, W.; McIntosh, L.; Eisenhauer, E. Randomized trial of two intravenous schedules of the topoisomerase I ihibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the National Cancer Institute of Canada clinical trials group J. Clin. Oncol. 2005, 23, 1859-1866
243. Yu, N. Y.; Conway, C.; Pena, R. L. S.; Chen, J. Y. STEALTH Liposomal CKD-602, a topoisomerase I inhibitor, improves teh therapeutic index in human tumor xenograft models Anticancer Res. 2007, 27, 2541-2546
244. Zamboni, W. C.; Strychor, S.; Joseph, E.; Walsh, D. R.; Zamboni, B. A.; Parise, R. A.; Tonda, M. E.; Yu, N. Y.; Engbers, C.; Eiseman, J. L. Plasma, tumor and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts Clin. Cancer Res. 2007, 13, 7217-7223
245. Zamboni, W. C.; Ramalingam, S.; Friedland, D. M.; Edwards, R. P.; Stoller, R. G.; Strychor, S.; Maruca, L.; Zamboni, B. A.; Belani, C. P.; Ramanathan, R. K. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies Clin. Cancer Res. 2009, 15, 1466-1472
246. Kunii, R.; Onishi, H.; Machida, Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin Eur. J. Pharm. Biopharm 2007, 67, 9-17
247. Miura, H.; Onishi, H.; Sasatsu, M.; Machida, Y. Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin J. Controlled Release 2004, 97, 101-113
248. Zhang, L.; Hu, Y.; Jiang, X.; Yang, C.; Lu, W.; Yang, Y. H. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co- lactide) nanoparticles and their biodisribution in mice J. Controlled Release 2004, 96, 135-148
249. Min, K. H.; Park, K.; Kim, Y.-S.; Bae, S. M.; Lee, S.; Jo, H. G.; Park, R. W.; Kim, I.-S.; Jeong, S. Y.; Kim, K.; Kwon, I. C. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy J. Controlled Release 2008, 127, 208-218
250. Williams, J.; Lansdown, R.; Sweitzer, R.; Romanowski, M.; LaBell, R.; Ramaswami, R.; Unger, E. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors J. Controlled Release 2003, 91, 167-172
251. Dadashzadeh, S.; Derakhshandeh, K.; Shirazi, F. H. 9-Nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats Anti-Cancer Drugs 2008, 19, 805-811
252. Lu, J.-L.; Wang, J.-C.; Zhao, S.-X.; Liu, X.-Y.; Zhao, H.; Zhang, X.; Zhou, S.-F.; Zhang, Q. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice Eur. J. Pharm. Biopharm 2008, 69, 899-907
253. Chenite, A.; Chaput, C.; Wang, D.; Combes, C.; Buschmann, M.; Hoemann, C. D.; Leroux, J. C.; Atkinson, B. L.; Binette, F.; Selmani, A. Novel injectable neutral solutions of chitosan fom biodegradable gels in situ Biomaterials 2000, 21, 2155-2161
254. Chenite, A.; Buschmann, M.; Wang, D.; Chaput, C.; Kndani, N. Rheological
255. Jarry, C.; Chaput, C.; Chenite, A.; Renaud, M. A.; Buschmann, M.; Leroux, J. C. Effects of steam sterilization on thermogelling chitosan-based gels J. Biomed. Mater. Res. 2001, 58, 127-135
256. Berrada, M.; Serreqi, A.; Dabbarh, F.; Owusu, A.; Gupta, A.; Lehnert, S. A novel non-toxic camptothecin formulation ofr cancer chemotherapy Biomaterials 2005, 26, 2115-2120
257. Yu, L.; Chang, G. T.; Zhang, H.; Ding, J. D. Injectable block copolymer hydrogels for sustained release of a PEGylated drug Int. J. Pharm. 2007, 348, 95-106
258. Lalloo, A.; Chao, P.; Hu, P.; Stein, S.; Sinko, P. J. Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins J. Controlled Release 2006, 112, 333-342
259. Koizumi, F.; Kitagawa, M.; Negishi, T.; Onda, T.; Matsumoto, S.-I.; Hamaguchi, T.; Matsumura, Y. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors Cancer Res. 2006, 66, 10048-10056
260. Sumitomo, M.; Koizumi, F.; Asano, T.; Horiguchi, A.; Ito, K.; Asano, T.; Kakizoe, T.; Hayakawa, M.; Matsumura, Y. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression Cancer Res. 2008, 68, 1631-1635
261. Nakajima, T. E.; Yanagihara, K.; Takigahira, M.; Yasunaga, M.; Kato, K.; Hamaguchi, T.; Yamada, Y.; Shimada, Y.; Mihara, K.; Ochiya, T.; Matsumura, Y. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan Cancer Res. 2008, 68, 9318-9322
262. Saito, Y.; Yasunaga, M.; Kuroda, J.; Koga, Y.; Matsumura, Y. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor Cancer Sci. 2008, 99, 1258-1264
263. Kuroda, J.; Kuratsu, J.-I.; Yasunaga, M.; Koga, Y.; Saito, Y.; Matsumura, Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma Int. J. Cancer 2009, 124, 2505-2511
264. Nakajima, T. E.; Yasunaga, M.; Kano, Y.; Koizumi, F.; Kato, K.; Hamaguchi, T.; Yamada, Y.; Shirao, K.; Shimada, Y.; Matsumura, Y. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-flurouracil Int. J. Cancer 2008, 122, 2148-2153
265. Nagano, T.; Yasunaga, M.; Goto, K.; Kenmotsu, H.; Koga, Y.; Kuroda, J.; Nishimura, Y.; Sugino, T.; Matsumura, Y. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment Clin. Cancer Res. 2009, 15, 4348-4355
266. Greenwald, R.; Pendri, A.; Conover, C.; Gilbert, C.; Yang, R.; Xia, J. Drug delivery systems. 2.Camptothecin-20-O-poly(ethylene glycol) ester transport forms J. Med. Chem. 1996, 39, 1938-1940
267. Conover, C. D.; Pendri, A.; Lee, C.; Gilbert, C. W.; Shum, K. L.; Greenwald, R. B. Camptothecin delivery systems: the antitumor activity of a camptothecin-20-O-polyethylene glycol ester transport form Anticancer Res. 1997, 17, 3361-3368
268. Conover, C. D.; Greenwald, R. B.; Pendri, A.; Gilbert, C.; Shum, K. L. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker Cancer Chemother. Pharmacol. 1998, 42, 407-414 (Pubitemid 28430372)
269. Rowinsky, E. K.; Rizzo, J.; Ochoa, L.; Takimoto, C. H.; Forouzesh, B.; Schwartz, G.; Hammond, L. A.; Patnaik, A.; Kwiatek, J.; Goetz, A.; Denis, L.; McGuire, J.; Tolcher, A. W. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-h infusion every 3 weeks in patients with advanced solid malignancies J. Clin. Oncol. 2003, 21, 148-157 (Pubitemid 37499473)
270. Posey, J. A., III; Saif, M. W.; Carlisle, R.; Goetz, A.; Rizzo, J.; Stevenson, S.; Rudoltz, M. S.; Kwiatek, J.; Simmons, P.; Rowinsky, E. K.; Takimoto, C. H.; Tolcher, A. W. Phase I study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas Clin. Cancer Res. 2005, 11, 7866-7871 (Pubitemid 41611632)
271. Scott, L. C.; Yao, J. C.; Benson, A. B., III; Thomas, A. L.; Falk, S.; Mena, R. R.; Picus, J.; Wright, J.; Mulcahy, M. F.; Ajani, J. A.; Evans, T. R. J. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma Cancer Chemother. Pharmacol. 2009, 63, 363-370
272. Cheng, J.; Khin, K. T.; Davis, M. E. Antitumor activity of β-cyclodextrin polymer-camptothecin conjugates Mol. Pharmaceutics 2004, 1, 183-193
273. Schluep, T.; Cheng, J.; Khin, K. T.; Davis, M. E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice Cancer Chemother. Pharmacol. 2006, 57, 654-662 (Pubitemid 43237851)
274. Schluep, T.; Hwang, J.; Cheng, J.; Heidel, J. D.; Bartlett, D. W.; Hollister, B.; Davis, M. E. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models Clin. Cancer Res. 2006, 12, 1606-1614
275. Lee, N.-J.; Ju, S.-S.; Cho, W.-J.; Kim, S.-H.; Kang, K.-T.; Brady, T.; Theodorakis, E. A. Synthesis and biological activity of medium molecular weight polymers of camptothecin Eur. Polym. J. 2003, 39, 367-374 (Pubitemid 35432647)
276. Lee, N.-J.; Ju, S.-S.; Cho, W.-J.; Kim, S.-H.; Kang, K.-T.; Brady, T.; Theodorakis, E. A. Synthesis and antitumor activity of medium molecular weight phthalimide polymers of camptothecin Polym. Int. 2003, 52, 1339-1345 (Pubitemid 36996939)
277. Zou, Y.; Wu, Q.-P.; Tansey, W.; Chow, D.; Hung, M.-C.; Charnsangavej, C.; Wallace, S.; Li, C. Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice Int. J. Oncol. 2001, 18, 331-336
278. Singer, J. W.; Bhatt, R.; Tulinsky, J.; Buhler, K. R.; Heasley, E.; Klein, P.; de Vries, P. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo J. Controlled Release 2001, 74, 243-247 (Pubitemid 32727627)
279. Bhatt, R.; de Vries, P.; Tulinsky, J.; Bellamy, G.; Baker, B.; Singer, J. W.; Klein, P. Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin J. Med. Chem. 2003, 46, 190-193 (Pubitemid 36043799)
280. Homsi, J.; Simon, G. R.; Garrett, C. R.; Springett, G.; De Conti, R.; Chiappori, A. A.; Munster, P. N.; Burton, M. K.; Stromatt, S.; Allievi, C.; Angiuli, P.; Eisenfeld, A.; Sullivan, D. M.; Daud, A. I. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies Clin. Cancer Res. 2007, 13, 5855-5861
281. Caiolfa, V. R.; Zamai, M.; Fiorino, A.; Frigerio, E.; Pellizzoni, C.; d'Argy, R.; Ghigleri, A.; Castelli, M. G.; Farao, M.; Pesenti, E.; Gigli, M.; Angelucci, F.; Suarato, A. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies J. Controlled Release 2000, 65, 105-119
282. Zamai, M.; vandeVen, M.; Farao, M.; Gratton, E.; Ghigleri, A.; Castelli, M. G.; Fontana, E.; d'Argy, R.; Fiorino, A.; Pesenti, E.; Suarato, A.; Caiolfa, V. R. Camptothecin poly[N-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy Mol. Cancer Ther. 2003, 2, 29-40
283. Schoemaker, N. E.; van Kesteren, C.; Rosing, H.; Jansen, S.; Swart, M.; Lieverst, J.; Fraier, D.; Breda, M.; Pellizzoni, C.; Spinelli, R.; Grazia Porro, M.; Beijnen, J. H.; Schellens, J. H. M.; ten Bokkel Huinink, W. W. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin Br. J. Cancer 2002, 87, 608-614
284. Wachters, F. M.; Groen, H. J. M.; Maring, J. G.; Gietema, J. A.; Porro, M. G.; Dumez, H.; de Vries, E. G. E.; van Oosterom, A. T. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4 week cycle in adult patients with solid tumours Br. J. Cancer 2004, 90, 2261-2267
285. Bissett, D.; Cassidy, J.; de Bono, J. S.; Muirhead, F.; Main, M.; Robson, L.; Fraier, D.; Magne, M. L.; Pellizzoni, C.; Porro, M. G.; Spinelli, R.; Speed, W.; Twelves, C. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT) Br. J. Cancer 2004, 91, 50-55
286. Sarapa, N.; Britto, M. R.; Speed, W.; Jannuzzo, M. G.; Breda, M.; James, C. A.; Porro, M. G.; Rocchetti, M.; Wanders, A.; Mahteme, H.; Nygren, P. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma Cancer Chemother. Pharmacol. 2003, 52, 424-430
287. Harada, M.; Sakakibara, H.; Yano, T.; Suzuki, T.; Okuno, S. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate J. Controlled Release 2000, 69, 399-412
288. Okuno, S.; Harada, M.; Yano, T.; Yano, S.; Kiuchi, S.; Tsuda, N.; Sakamura, Y.; Imai, J.; Kawaguchi, T.; Tsujihara, K. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128) Cancer Res. 2000, 60, 2988-2995
289. Harada, M.; Imai, J.; Okuno, S.; Suzuki, T. Macrophage-mediated activation of camptothecin analogue T-2513-carboxymethyl dextran conjugate (T-0128): possible cellular mechanism for antitumor activity J. Controlled Release 2000, 69, 389-397
290. Binaschi, M.; Parlani, M.; Bellarosa, D.; Bigioni, M.; Salvatore, C.; Palma, C.; Crea, A.; Maggi, C. A.; Manzini, S.; Goso, C. Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate Anti-Cancer Drugs 2006, 17, 1119-1126
291. Harada, M.; Murata, J.-I.; Sakamura, Y.; Sakakibara, H.; Okuno, S.; Suzuki, T. Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats J. Controlled Release 2001, 71, 71-86 (Pubitemid 32195442)
292. Fujita, F.; Koike, M.; Fujita, M.; Sakamoto, Y.; Okuno, S.; Kawaguchi, T.; Yano, S.; Yano, T.; Kiuchi, S.; Fujiwara, T.; Kudoh, S.; Kakushima, M. MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice Clin. Cancer Res. 2005, 11, 1650-1657 (Pubitemid 40315250)
293. Inoue, K.; Kumazawa, E.; Kuga, H.; Susaki, H.; Masubuchi, N.; Kajimura, T., CM-dextran-polyalcohol-camptothecin conjugate. In Polymer Drugs in the Clinical Stage; Maeda, H., Ed.; Kluwer Academic/Plenum Publishers: New York, 2003.
294. Kumazawa, E.; Ochi, Y. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: Potent antitumor activities in various murine models Cancer Sci. 2004, 95, 168-175 (Pubitemid 38404319)
295. Ochi, Y.; Shiose, Y.; Kuga, H.; Kumazawa, E. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951 Cancer Chemother. Pharmacol. 2005, 55, 323-332 (Pubitemid 40379255)
296. Shiose, Y.; Ochi, Y.; Kuga, H.; Yamashita, F.; Hashida, M. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors Biol. Pharm. Bull. 2007, 30, 2365-2370 (Pubitemid 350223744)
297. Kato, M.; Matsuhashi, K.; Shimomura, K.; Shimada, M.; Hagiwara, M.; Fujikawa, K.; Furuhama, K. Examination of meningocele induced by the antitumor agent DE-310 in rat fetuses Reprod. Toxicol. 2005, 20, 495-502 (Pubitemid 41393840)
298. Soepenberg, O.; De Jonge, M. J.; Sparrenboom, A.; de Bruin, P.; Eskens, F. A. L. M.; de Heus, G.; Wanders, J.; Cheverton, P.; Ducharme, M. P.; Verweij, J. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors Clin. Cancer Res. 2005, 11, 703-711 (Pubitemid 40116898)
299. Wente, M. N.; Kleeff, J.; Buchler, M. W.; Wanders, J.; Cheverton, P.; Langman, S.; Friess, H. DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors Invest. New Drugs 2005, 23, 339-347 (Pubitemid 40980356)
300. Yurkovetskiy, A. V.; Fram, R. J. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer Adv. Drug Delivery Rev. 2009, 61, 1193 - 1202
301. Sapra, P.; Zhao, H.; Mehling, M.; Malaby, J.; Kraft, P.; Longley, C.; Greenberger, L. M.; Horak, I. D. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11- refractory model Clin. Cancer Res. 2008, 14, 1888-1896 (Pubitemid 351469476)
302. Zhao, H.; Rubio, B.; Sapra, P.; Wu, D.; Reddy, P.; Sai, P.; Martinez, A.; Gao, Y.; Lozanguiez, Y.; Longley, C.; Greenberger, L. M.; Horak, I. D. Novel prodrugs of SN38 using multiarm poly(etylene glycol) linkers Bioconjugate Chem. 2008, 19, 849-859 (Pubitemid 351614540)
303. Fox, M. E.; Guillaudeu, S.; Fréchet, J. M. J.; Jerger, K.; Macaraeg, N.; Szoka, F. C. Synthesis and in vivo antitumor efficacy of PEGylated poly(L-lysine) dendrimer-camptothecin conjugates Mol. Pharmaceutics 2009, 6, 1562-1572
304. Warnecke, A.; Kratz, F. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy Bioconjugate Chem. 2003, 14, 377-387 (Pubitemid 36348661)
305. Schmid, B.; Chung, D.-E.; Warnecke, A.; Fichtner, I.; Kratz, F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy Bioconjugate Chem. 2007, 18, 702-716 (Pubitemid 47010789)
306. Schmid, B.; Warnecke, A.; Fichtner, I.; Jung, M.; Kratz, F. Development of albumin-binding comptothecin prodrugs using a peptide positional scanning library Bioconjugate Chem. 2007, 18, 1786-1799 (Pubitemid 350219976)
307. Moon, S.-J.; Govindan, S. V.; Cardillo, T. M.; D'Souza, C. A.; Hansen, H. J.; Goldenberg, D. M. Antibody conjugates of 7-ethyl-10-hydoxycamptothecin (SN-38) for targeted cancer chemotherapy J. Med. Chem. 2008, 51, 6916-6929
308. Dharap, S. S.; Wang, Y.; Chandna, P.; Khandare, J. J.; Qiu, B.; Gunaseelan, S.; Sinko, P. J.; Stein, S.; Farmanfarmaian, A.; Minko, T. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12962-12967
309. Chandna, P.; Saad, M.; Wang, Y.; Ber, E.; Khandare, J. J.; Vetcher, A. A.; Soldatenkov, V. A.; Minko, T. Targeted proapoptotic anticancer drug delivery system Mol. Pharmaceutics 2007, 4, 668-678
310. Meyer-Losic, F.; Nicolazzi, C.; Quinnero, J.; Ribes, F.; Michel, M.; Dubois, V.; de Coupade, C.; Boukaissi, M.; Chene, A.-S.; Tranchant, I.; Arranz, V.; Zoubaa, I.; Fruchart, J.-S.; Ravel, D.; Kearsey, J. DTS-108, a novel peptidic prodrug of SN38: In vivo efficacy and toxicokinetic studies Clin. Cancer Res. 2008, 14, 2145-2153
311. Sparrenboom, A.; Gelderbolm, H.; Marsh, S.; Ahluwalia, R.; Obach, R.; Principe, P.; Twelves, C.; Verweij, J.; McLeod, H. L. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype Clin. Pharmacol. Ther. 2004, 76, 38-44
312. Rajendra, R.; Grounder, M. K.; Saleem, A.; Schellens, J. H.; Ross, D. D.; Bates, S. E.; Sinko, P. J.; Rubin, E. H. Differential effects of the breat cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin Cancer Res. 2003, 63, 3228-3233
313. Nakatomi, K.; Yoshikawa, M.; Oka, M.; Y., I.; Hayasaka, S.; Sano, K.; Shiozawa, K.; Kawabata, S.; Soda, H.; Ishikawa, T.; Tanabe, S.; Kohno, S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells Biochem. Biophys. Res. Commun. 2001, 288, 827-832
314. Maliepaard, M.; van Gastelen, M. A.; de Jong, L. A.; Pluim, D.; van Waardenburg, R. C.; Ruevekamp-Helmers, M. C.; Floot, B. G.; Schellens, J. H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line Cancer Res. 1999, 59, 4559-4563